PCRX Shareholders Invited to Spearhead Class Action Lawsuit Against Pacira BioSciences for Alleged Securities Fraud
Investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) are presented with a significant opportunity as the deadline approaches to apply as lead plaintiff in a securities fraud lawsuit. The case under consideration alleges misleading statements by the company, potentially impacting shareholder investments. Investors who have suffered losses connected to Pacira’s actions, particularly during the period between April 23, 2021, and August 9, 2022, are urged to step forward. The lawsuit, managed by The Schall Law Firm, a Los Angeles-based firm with expertise in securities class action and shareholder rights litigation, focuses on how the company might … Read more